Market Overview

Will The U.K.'s Business Department Block Pfizer's Bid?

Related PFE
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Johnson & Johnson's Robust Pipeline Supports Its Above-Average Valuation
My Dividend Growth Portfolio - Q3 2016 Summary (Seeking Alpha)
Related AZN
AstraZeneca Drug Trial Failure Has Major Implications To Its Pipeline
A Peek Into The Markets: U.S. Stock Futures Edge Higher; Crude Oil Drops

UPDATE: Since the original posting of this note, shares of AstraZeneca have almost fully recovered. Recent Bloomberg news now suggests that the United Kingdom's Business Department is Neutral on the Pfizer deal.

Bloomberg on Friday reported that the United Kingdom's Business Department is searching for solutions to block Pfizer's (NYSE: PFE) bid for AstraZeneca PLC (NYSE: AZN).

Bloomberg reporter Robert Hutton stated that the U.K.'s Business Department “is looking at how Pfizer Inc.'s proposed takeover of AstraZeneca Plc could be blocked on public interest grounds.”

Bloomberg's source specified that Business Secretary Vince Cable could discuss the case to the European Commission. Another solution includes an amendment to the Enterprise Act, which would widen “public interest” specifically for takeovers.

Shares of AstraZeneca fell more than eight percent to $72.79 Friday morning, but have slightly recovered. The stock is currently trading at $77.40, down 1.7 percent.

Shares of Pfizer are following a more upward parabolic trend on Friday. The stock is down roughly a half of a percent at $29.00.

Posted-In: BloombergNews Rumors Media


Related Articles (AZN + PFE)

View Comments and Join the Discussion!